Oxford Biomedica. 2005 to see 'Huge value creation' (Panmure Gordon)

rrr,
I don't know, but I doubt anyone else does - immunotherapy is just a chick emerging from its shell, if you'll excuse the pun.

david,
Thanks for the EVO note last night. Re your 26010, I would have thought it's just that institutions take time to get organised and authorised when coming back to market to add. But I think you know more about that than me. It could also be that the Genentech rumour has just reached our buyer today too.

All re. Genentech,
Since Trovax is a potential competitor to Avastin, I would seriously hope any bid didn't sound the death knell for a promising therapy, but the possibility concerns me.
DD